Zurcher Kantonalbank Zurich Cantonalbank Grows Position in Danaher Co. (NYSE:DHR)

Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Danaher Co. (NYSE:DHR) by 1.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 301,039 shares of the conglomerate’s stock after acquiring an additional 3,673 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Danaher were worth $83,695,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Benjamin Edwards Inc. lifted its position in Danaher by 1.8% during the second quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock valued at $538,000 after purchasing an additional 38 shares during the last quarter. Wedge Capital Management L L P NC lifted its holdings in shares of Danaher by 3.2% in the 3rd quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock valued at $342,000 after acquiring an additional 38 shares during the last quarter. Patrick M Sweeney & Associates Inc. increased its stake in Danaher by 3.4% during the second quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock worth $307,000 after acquiring an additional 40 shares during the last quarter. Trust Co of Kansas lifted its stake in shares of Danaher by 4.1% in the 2nd quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock valued at $255,000 after purchasing an additional 40 shares during the last quarter. Finally, Abacus Planning Group Inc. lifted its stake in shares of Danaher by 0.7% in the 2nd quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock valued at $1,359,000 after purchasing an additional 40 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Performance

DHR opened at $238.90 on Thursday. The stock has a market cap of $172.55 billion, a P/E ratio of 45.59, a P/E/G ratio of 4.37 and a beta of 0.85. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The firm has a fifty day moving average price of $256.00 and a 200 day moving average price of $259.66. Danaher Co. has a 1 year low of $215.68 and a 1 year high of $281.70.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The company’s quarterly revenue was up 3.1% on a year-over-year basis. During the same period last year, the firm earned $2.02 EPS. Equities research analysts anticipate that Danaher Co. will post 7.5 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were given a dividend of $0.27 per share. The ex-dividend date was Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. Danaher’s dividend payout ratio (DPR) is 20.61%.

Analyst Ratings Changes

DHR has been the topic of a number of analyst reports. Royal Bank of Canada cut their price objective on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Evercore ISI raised their price target on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Robert W. Baird lowered their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Stifel Nicolaus raised their target price on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research report on Wednesday, October 23rd. Finally, Raymond James lowered their price target on Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $287.16.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.